BioNTech SE (BNTX) said its financial performance has been fully in line with the company's expectations for the first quarter of 2023. Commercial revenues decreased due to lower demand for COVID-19 vaccine.
For fiscal 2023, the company continues to project BioNTech COVID-19 vaccine revenues of approximately 5 billion euros. In 2023, the company plans to deliver doses originally scheduled for delivery in 2022 in some geographies. BioNTech SE said, for the remainder of 2023, the company is focused on advancing its disruptive platforms against solid tumors and accelerating clinical programs in infectious diseases of high global need.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.